Fagron SA is a pharmaceutical compounding company operating in Belgium. It acts as a supplier of pharmaceutical care to hospitals, pharmacies, clinics, and patients across the world. The company also produces pharmaceutical raw materials, equipment, and supplies that are needed to prepare medication in the pharmacy. Its segments are namely Fagron Europe, Middle East and Africa (EMEA), Fagron North America, and Fagron Latin America. The majority of its revenue comes from Fagron North America.
1990
4.0K+
LTM Revenue $963M
LTM EBITDA $192M
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fagron has a last 12-month revenue of $963M and a last 12-month EBITDA of $192M.
In the most recent fiscal year, Fagron achieved revenue of $937M and an EBITDA of $170M.
Fagron expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Fagron valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $820M | $937M | XXX | XXX | XXX |
Gross Profit | $307M | $357M | XXX | XXX | XXX |
Gross Margin | 38% | 38% | XXX | XXX | XXX |
EBITDA | $144M | $170M | XXX | XXX | XXX |
EBITDA Margin | 18% | 18% | XXX | XXX | XXX |
Net Profit | $74.8M | $75.8M | XXX | XXX | XXX |
Net Margin | 9% | 8% | XXX | XXX | XXX |
Net Debt | $248M | $206M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Fagron's stock price is EUR 19 (or $21).
Fagron has current market cap of EUR 1.4B (or $1.5B), and EV of EUR 1.7B (or $1.8B).
See Fagron trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$1.8B | $1.5B | XXX | XXX | XXX | XXX | $1.28 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Fagron has market cap of $1.5B and EV of $1.8B.
Fagron's trades at 1.9x LTM EV/Revenue multiple, and 9.4x LTM EBITDA.
Analysts estimate Fagron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Fagron and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $1.8B | XXX | XXX | XXX |
EV/Revenue | 1.9x | XXX | XXX | XXX |
EV/EBITDA | 10.7x | XXX | XXX | XXX |
P/E | 17.6x | XXX | XXX | XXX |
P/E/Growth | 1.0x | XXX | XXX | XXX |
EV/FCF | 24.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpFagron's NTM/LTM revenue growth is 9%
Fagron's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Fagron's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Fagron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Fagron and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 14% | XXX | XXX | XXX | XXX |
EBITDA Margin | 18% | XXX | XXX | XXX | XXX |
EBITDA Growth | 18% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 27% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
Opex to Revenue | 30% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fagron acquired XXX companies to date.
Last acquisition by Fagron was XXXXXXXX, XXXXX XXXXX XXXXXX . Fagron acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Fagron founded? | Fagron was founded in 1990. |
Where is Fagron headquartered? | Fagron is headquartered in Belgium. |
How many employees does Fagron have? | As of today, Fagron has 4.0K+ employees. |
Who is the CEO of Fagron? | Fagron's CEO is Mr. Rafael Padilla. |
Is Fagron publicy listed? | Yes, Fagron is a public company listed on BRU. |
What is the stock symbol of Fagron? | Fagron trades under FAGR ticker. |
When did Fagron go public? | Fagron went public in 2007. |
Who are competitors of Fagron? | Similar companies to Fagron include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
What is the current market cap of Fagron? | Fagron's current market cap is $1.5B |
What is the current revenue of Fagron? | Fagron's last 12-month revenue is $963M. |
What is the current EBITDA of Fagron? | Fagron's last 12-month EBITDA is $192M. |
What is the current EV/Revenue multiple of Fagron? | Current revenue multiple of Fagron is 1.9x. |
What is the current EV/EBITDA multiple of Fagron? | Current EBITDA multiple of Fagron is 9.4x. |
What is the current revenue growth of Fagron? | Fagron revenue growth between 2023 and 2024 was 14%. |
Is Fagron profitable? | Yes, Fagron is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.